How much is Mediphage worth in 2026?

Mediphage has a current valuation of N/A based on their Accelerator/Incubator round and secondary market data.

How much funding has Mediphage raised?

Mediphage has raised $4.1M in total funding across 1 funding rounds.

Mediphage

Drug DiscoveryWebsite

Mediphage valuation and funding history | Last updated: January 1, 2025 | 1 funding rounds

Current Valuation

N/A

As of January 1, 2025

Total Funding Raised

$4.1M

Across 1 round

Last Round

Accelerator/Incubator

$3.3M

Last Funding

Jan 2025

Funding date

Capital Efficiency

N/A

Valuation / Funding

Funding History & Valuation Timeline

Complete history of all funding rounds and valuation milestones

Date	Round	Amount	Post-Valuation	Growth
December 16, 2021	Seed Round	$3.3M	N/A	-

Valuation Analysis

Current Valuation Metrics

Mediphage is currently valued at N/A as of January 1, 2025. The company has raised a total of $4.1M in funding across 1 funding round.

Track Mediphage Valuation Updates

Get notified when Mediphage raises new funding or valuation changes

Explore More Data

Detailed analysis for Mediphage

Secondary Market Price

Real-time pricing data and trends

Valuation Tracker

Historical valuation changes

Funding History

Complete funding round timeline

Secondary Price History

Historical transaction data

All Investors

Complete list of all investors

View 5 companies free

Create a free account to unlock Mediphage's valuation history, funding rounds, and growth metrics.

No credit card required

What is Mediphage Worth in 2026?

Mediphage is a leading private company in the Drug Discovery sector. Track Mediphage's valuation history, funding timeline, and implied market value from secondary transactions on Premier Alternatives.

How Mediphage Valuation is Determined

Private company valuations like Mediphage's are determined through primary funding rounds led by venture capital firms, private equity investors, and strategic partners. The valuation reflects factors including revenue growth, market opportunity, competitive positioning, and investor sentiment.